Hims & Hers stock falls 10% on revenue miss

Hims & Hers Health shares fell 9% in extended trading after reporting Q2 revenue of $544.8 million, which missed Wall Street estimates, and providing Q3 adjusted EBITDA guidance of $60-70 million, below analyst expectations. Despite beating Q2 adjusted EPS and adjusted EBITDA, the revenue miss and conservative forward outlook, alongside ongoing controversy regarding its continued sale of compounded GLP-1s following a failed Novo Nordisk partnership and FDA statements on resolved branded drug supply issues, appear to have weighed on investor sentiment.

Analysis

Hims & Hers Health experienced a 9% share price decline in extended trading, driven primarily by a second-quarter revenue miss and a significantly weaker-than-expected third-quarter outlook. The company reported Q2 revenue of $544.8 million, falling short of the $552 million analyst consensus. More critically, its Q3 adjusted EBITDA guidance of $60 million to $70 million was substantially below the $77.1 million anticipated by StreetAccount. This pessimistic guidance overshadowed positive aspects of the Q2 report, including a beat on adjusted EPS at 17 cents versus 15 cents expected, and robust year-over-year performance, with revenue increasing 73% and net income rising to $42.5 million from $13.3 million a year prior. The market's negative reaction is amplified by significant regulatory and legal risks associated with Hims & Hers' continued sale of compounded GLP-1s. This practice persists despite the FDA's statement that branded drug shortages have been resolved and follows a public and acrimonious end to a partnership with Novo Nordisk, which accused Hims of failing to 'adhere to the law'.

Key Decisions for Investors

• Investors should scrutinize the upcoming investor call for management's explanation of the significant shortfall in Q3 adjusted EBITDA guidance, as this is a key driver of the negative market reaction.
• The ongoing sale of compounded GLP-1s, following the public dispute with Novo Nordisk and FDA statements, represents a material legal and regulatory risk that must be closely monitored for potential impact on future revenue streams.
• While the 73% year-over-year revenue growth is strong, it must be evaluated against the current revenue miss relative to expectations and the significant legal overhang that could threaten a key growth driver.
• The 9% stock decline reflects a valuation reset, but a long position requires a high tolerance for the legal and regulatory uncertainties surrounding the company's GLP-1 business model.